Syncom Formulations (India) — 360° view

Syncom Formulations (India), a company in the Pharmaceuticals industry, reported revenue of ₹137 crore and net profit of ₹25 crore for the September 2026 quarter.

Syncom Formulations (India) (NSE: SYNCOMF) closed at ₹21.90 on 20 Nov 2026, up 36.9% over the past year. Its market capitalisation is ₹2,059 crore and it trades at 22.0 times earnings.

Share price
₹21.90 (20 Nov 2026)
Market cap
₹2,059 Cr (20 Nov 2026)
P/E
22.04 (20 Nov 2026)
Revenue
₹137 Cr (September 2026 quarter)
Net profit
₹25 Cr (September 2026 quarter)
ROCE
24.8% (FY26)
ROE
17.6% (FY26)
Book value
₹4.95 (FY26)
Dividend yield
0.46% (last 12 months to 20 Nov 2026)
52-week high / low
₹27.49 / ₹10.21 (20 Nov 2026)
1-year return
36.9% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SYNCOMF

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.